Breast Awareness, Self-Reported Abnormalities, and Breast Cancer in Rural Ethiopia: A Survey of 7,573 Women and Predictions of the National Burden

Wondimu Ayele, Adamu Addisie, Andreas Wienke, Susanne Unverzagt, Ahmedin Jemal, Lesley Taylor, Eva J. Kantelhardt

School of Public Health Department of Biostatistics and Epidemiology, Addis Ababa University, Ethiopia; Institute of Medical Epidemiology, Biometrics and Informatics and Department of Gynaecology, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany; America Cancer Society, Atlanta, Georgia, USA; City of Hope National Medical Center, Duarte, California, USA

Disclosures of potential conflicts of interest may be found at the end of this article.

Key Words: Breast neoplasms • Health services • Ethiopia

ABSTRACT

Background. Breast cancer (BC) is the most frequently diagnosed cancer and leading cause of cancer deaths among women in low-income countries. Ethiopia does not have a national BC screening program, and over 80% of patients are diagnosed with advanced stage disease. The aim of this study was to assess how many women self-report a breast abnormality and to determine their diagnoses in rural Ethiopia.

Methods. A community-based cross-sectional study was conducted among 7,573 adult women. Women were interviewed and educated about breast awareness, and those who reported breast abnormalities underwent clinical examination by experienced surgeons. Ultrasound-guided fine needle aspiration cytology (FNAC) was obtained, and cytological analysis was performed. The findings were projected to the female population of Ethiopia to estimate current and future burden of diseases.

Findings. Of the 7,573 women surveyed, 258 (3.4%) reported a breast abnormality, 246 (3.2%) received a physical examination, and 49 (0.6%) were found to be eligible for ultrasound-guided FNAC or nipple discharge evaluation. Of all the cases, five (10.2%) breast malignancies were diagnosed. We projected for Ethiopia that, approximately, 1 million women could self-report a breast abnormality, 200,000 women could have a palpable breast mass, and 28,000 women could have BC in the country.

Conclusion. The health care system needs to build capacity to assess and diagnose breast diseases in rural areas of Ethiopia. These data can be used for resource allocation to meet immediate health care needs and to promote detecting and treating BC at earlier stages of disease.

The Oncologist 2021;26:e1009–e1017

Implications for Practice: Routine mammography screening in a resource-limited country with a young population is neither sensitive nor affordable. Clinical breast examination with consecutive ultrasound-guided fine needle aspiration cytology may ensure early diagnosis, downstage disease, and reduce breast cancer mortality. This study had the unique opportunity to educate over 7,573 rural women about breast abnormalities and offer clinical and cytological diagnosis for reported breast abnormalities. The findings were extrapolated to show the nationwide burden of breast abnormalities and unmet diagnostic needs. These data will serve as policy guide to improve adequate referral mechanisms and breast diagnostic and treatment facilities.

INTRODUCTION

In Ethiopia, breast cancer (BC) is the most frequently diagnosed and most prevalent cancer in women, as well as the second leading cause of cancer death. The recent publication of GLOBOCAN estimates an annual number of 15,244
new cases and 8,159 deaths. A reported 25,156 women have been diagnosed with BC over the last 5 years [1–3]. This number is comparable to the estimated number of pregnancy-related deaths in the country, but BC care remains underfunded and underdeveloped. For a country of 107 million people, one centralized comprehensive cancer center with one radiation machine exists in the capital city of Addis Ababa. Patients with BC suffer from poor survival and are often diagnosed at a young age [4–5]. BC screening programs are not in place, and more than 80% of BCs are diagnosed at an advanced stage. Early detection of BC is an optimal approach to reduce premature BC deaths in developing countries [6–7]. Routine BC screening using mammography in a country with a young population is less sensitive, unaffordable, and not feasible in a resourcelimited setting like Ethiopia [8–11]. Clinical breast examination followed by ultrasound-guided fine needle aspiration cytology (FNAC) is a simple and effective strategy to downstage disease and reduce BC mortality in resourcelimited countries [12]. Studies have documented that the strategy is efficient without serious complications or adverse effects for the patients [13–17]. Clinical breast examination is recommended by guidelines [18] and was recently introduced in Ethiopia. To reach the general population, examination by lay volunteers has been shown to be effective but involves high costs [19]. This study aimed to assess and offer a diagnostic workup for women with self-reported breast abnormalities to investigate the magnitude of rural women who would use diagnostic services if public awareness and diagnostic health services were in place.

In the absence of up-to-date data on the magnitude of BC abnormalities and cancer in rural Ethiopia, developing tailored interventions for the future prevention and control of the disease are major challenges [20]. Identifying women with self-reported breast abnormalities provides the opportunity to detect untreated BC cases at early stages. The aim of this study was to estimate the proportion of adult women with self-reported breast abnormalities in a rural region of Ethiopia, assess the diagnosis of these abnormalities, and extrapolate the disease burden for the entire Ethiopian female population.

Materials and Methods

Study Design and Population

This community-based cross-sectional study was conducted at the Butajira Health and Demographic Surveillance Site (HDSS) in Ethiopia. The site is located in a densely populated area within a rural region in the South. The HDSS was created in 1986 to continuously collect longitudinal population health and health-related data and to provide infrastructure for additional studies. Currently, over 78,000 inhabitants are under surveillance in this site. The people reside in nine rural and one urban “kebeles” (neighborhoods) [21]. The kebeles are further classified based on geographic zones as highland, midland, and lowland areas. The area is considered a representative cross-section of Ethiopia’s diverse population and living conditions, as over 73% of Ethiopia’s female population lives in rural areas. Patients typically receive care in health posts or in health centers and then receive a more complex diagnostic workup and treatment for medical conditions in hospitals. In the context of BC, patients receive physical examination by surgeons, fine needle aspirations, surgeries, and endocrine therapies in the zonal hospital. Patients requiring chemotherapy or radiation would be sent to the regional hospital or to the national comprehensive cancer center, Black Lion Hospital, Addis Ababa, which at the time of this study has the country’s only radiation machine. The data for this study were collected from March 2018 to April 2018.

Sampling Size and Sampling Procedure

The sample size of 7,580 women was calculated using the single proportional sample size determination formula. In similar settings of rural patients in sub-Saharan Africa, the reported proportion of women with a self-detected breast abnormality had been found to be 3.5% [22]. We assumed 10% variation in our setting, assuming 95% confidence intervals (CIs) and 0.8% margin of error. We used a design effect of 2 for intra-kebele correlation and 10% upward adjustment for nonresponses. A two-stage stratified cluster sampling technique was used. The demographic information of nine kebeles were reviewed for number of houses and number of female residents. Three kebeles were located in the highland area, three in the midland area, and three in the lowland area. All of the kebeles were considered rural (as defined by central statistics agency concepts and definitions) [23], except for one kebele located in a midland area.

Data Collection and Variables

Data on self-reported breast abnormalities were collected based on a structured data collection tool with options for open responses and were adapted from the National Comprehensive Cancer Network guidelines [18]. Prior to the actual survey, an assessment was conducted and revealed that women preferred face-to-face interviews by female interviewers. Female data collectors, health extension workers, and supervisors were instructed on breast self-awareness and the signs, symptoms, risk factors, and interventions for breast abnormalities, including clinical assessment by a surgeon, ultrasound-guided FNAC, and referral within the health care system when needed.

Twenty female data collectors and two supervisors collected data on sociodemographic factors, gynecologic history, breast health awareness, and whether participants sought care for medical problems within the health care system or with traditional healers. Women were asked if they had any breast abnormalities, including nipple discharge, mass, skin changes, burning sensation, nipple retraction, redness, pain, or any other condition felt to be abnormal compared with baseline. Women who reported self-detected breast abnormalities were further asked about any past history of breast problems and whether the symptoms resolved or persisted. Those with active complaints were referred to the nearby health center for a physical examination by a surgeon and consideration of ultrasound-guided FNAC. The surgeon performed ultrasound-guided FNAC for palpable breast lesions and cytologic assessment of nipple discharge. An experienced pathologist interpreted the cytology slides. Women diagnosed with suspected BC were referred for oncologic
care at Butajira Hospital. Ethical clearance was obtained from the institutional review boards of the College of Health Science in Addis Ababa University. Written consent was obtained from each woman before starting the interview, and an informed consent was obtained from parents of participants between 15 and 18 years of age. Women with BC were linked to the nearby hospital for free oncology care.

Statistical Analysis
Data were checked for completeness and inconsistencies, entered into Epi Info version 3.5, and analyzed by statistical software SPSS version 23. Descriptive statistical methods were used to summarize sociodemographic, clinical, and pathologic characteristics and reported breast abnormalities. Projections of the burden of benign and malignant breast disease were computed as prevalence for the next 10 years. We assumed a moderate and rapid rate of Ethiopian population growth and increase in life expectancy [23–25]. Our predictions of future disease burden were based on projections from United Nations population data on the expected population growth and extrapolation within age-specific strata. Pearson chi-square and Fisher’s exact tests were used to assess the factors associated with self-reported breast abnormalities (Fig. 1).

RESULTS
Sociodemographic Characteristics
The mean ± SD age of the study participants was 35 ± 15 years. Breast abnormalities were self-reported more frequently among women between the age groups of 25–34 years and 35–49 years (p < .001). In our survey, 5,285 (69.8%) women lived in rural areas. We found that the majority of women, 5,066 (66.9%) were married, 3,944 (52.1%) had no formal education, 5,345 (70.6%) were Muslim, and 5,557 (73.4%) perceived themselves as having a “medium” economic status in their society (Table 1).

Breast Awareness, Symptoms of Abnormalities, and Treatment Sought
Of the total 7,573 women surveyed, 3,281 (43.3%) had heard about a breast examination, but only 1,188 (15.7%) had actually ever examined themselves. We found 256 (3.4%) women had current breast abnormalities. Women with reported breast abnormalities were asked about major symptoms: 130 (50.8%) reported pain, 91 (35.5%) reported a mass or lump and 7 (2.7%) reported nipple discharge. Respondents were asked for perceived causes of the symptoms: 169 (66.0%) mentioned sun stroke (locally known as “Mitch”), 57 (24.0 %) said “I do not know,” and 14 (5.5%) thought their breast problem was cancer.

Of the 256 women who reported active breast abnormalities, 107 (41.8%) said they sought treatment before. Of these, 85 (79.4%) sought care at health facilities, 10 (9.3%) went to a traditional healer, and 12 (11.2%) visited both traditional healers and health facilities.

The 107 women then were asked about the care they received: 66 (61.7%) had received medication, such as analgesics or antibiotics; 14 (13.1%) had surgery (excisional biopsy); and 8 (7.5%) received traditional medicine (Table 2).

Reproductive Health Characteristics
Of the 256 women with current breast abnormalities, 135 (52.7%) used modern family planning methods. Of these, 16 (10.7%) took oral contraceptives. The mean age of menarche for the study participants was 15 years ± 1 year, and the age of first live childbirth was 19.6 years ± 2.7 years. We observed that breast abnormalities were associated with use of modern family planning methods (p < .001), current breastfeeding (p < .001), early age of menarche (p < .001), and older age at first birth (p < .015) (Table 3).
Medical Comorbidities and Social and Family History

Of the 256 women with reported breast abnormalities, 19 (7.4%) indicated that they had other medical problems. We found 68 (26.6%) reported that they had chronic diseases, such as kidney diseases (24 or 9.4%), hypertension (10 or 3.9%), cardiac disease (5 or 2.0%), tuberculosis (4 or 1.6%), diabetes (1 or 0.4%), and other chronic diseases (not otherwise specified; 23 or 9.0%); 43 (16.8%) women reported a history of alcohol consumption, and 108 (42.2%) chewed khat, whereas we found that only two (0.03%) were ever smokers. A total of 33 (12.9%) women with reported breast abnormalities had a family history of BC, specifically, 25 (78.2%) in a first-degree relative (mother or sister) and 7 (21.2%) in a second-degree relative (uncles or aunts).

By comparison, 2.4% of women without self-reported breast abnormalities had a family history of BC (supplemental online Table 1). We found that self-reported breast abnormalities were associated with a family history of BC ($p < .001$), positive medical history of a chronic disease ($p < .001$), and a history of having an abnormality or mass in another part of the body ($p < .001$).

Diagnosis of Patients with Self-Reported Breast Abnormalities
We interviewed 7,573 women and found that 256 (3.8%) reported current breast abnormalities and 2 reported current known BC. Of the 256 women with self-reported current breast abnormalities, 246 (96.1%) underwent physical examination by a surgeon. The clinical diagnosis was documented. The surgeon determined that 121 (49.2%) women had breast tenderness or cyclical mastalgia, 54 (27.4%) had...
Table 3. Age and reproductive characteristics of study participants in Butajira Health and Demographic Surveillance Site, southern Ethiopia, 2018

| Age and reproductive characteristics | Women with a breast abnormality, n (%) | Women without a breast abnormality, n (%) | p value |
|--------------------------------------|----------------------------------------|-------------------------------------------|---------|
| 5-year age categories                |                                        |                                           |         |
| 15–19                                | 7 (2.7)                                | 1,103 (15.1)                              | .015    |
| 20–24                                | 33 (12.9)                              | 817 (11.2)                                |         |
| 25–29                                | 54 (21.1)                              | 1,092 (14.9)                              |         |
| 30–34                                | 49 (19.1)                              | 851 (11.9)                                |         |
| 35–39                                | 56 (21.9)                              | 1,014 (13.9)                              |         |
| 40–44                                | 21 (8.2)                               | 647 (8.8)                                 |         |
| 45–49                                | 13 (5.1)                               | 449 (6.1)                                 |         |
| 50–54                                | 12 (4.7)                               | 403 (5.5)                                 |         |
| 55–59                                | 4 (1.6)                                | 236 (3.2)                                 |         |
| 60–64                                | 4 (1.6)                                | 297 (4.1)                                 |         |
| ≤65                                  | 3 (1.2)                                | 408 (5.6)                                 |         |
| Ever used modern family planning     |                                        |                                           |         |
| Yes                                  | 135 (52.7)                             | 2,540 (34.7)                              | .001    |
| No                                   | 121 (47.3)                             | 4,777 (65.3)                              |         |
| Type of family planning used         |                                        |                                           |         |
| Pills                                 | 16 (10.7)                              | 310 (4.2)                                 |         |
| Implant                               | 24 (16.1)                              | 661 (9.0)                                 |         |
| Injectable/DPO                        | 95 (62.9)                              | 1,590 (21.7)                              |         |
| IUCD                                  | 1 (0.7)                                | 35 (0.5)                                  |         |
| Have you ever been pregnant?         |                                        |                                           |         |
| Yes                                  | 228 (89.1)                             | 5,574 (76.2)                              | .001    |
| No                                   | 28 (10.9)                              | 1,743 (23.8)                              |         |
| Are you currently breastfeeding?      |                                        |                                           |         |
| Yes                                  | 99 (43.9)                              | 1,788 (32.1)                              | .001    |
| No                                   | 130 (56.8)                             | 3,781 (67.9)                              |         |
| Age at menarche?                      |                                        |                                           |         |
| ≤11                                  | 11 (4.3)                               | 47 (0.6)                                  | .001    |
| 12                                   | 1 (0.4)                                | 165 (2.3)                                 |         |
| 13                                   | 17 (6.6)                               | 565 (7.7)                                 |         |
| 14                                   | 56 (21.9)                              | 1,624 (22.2)                              |         |
| ≥15                                  | 171 (66.8)                             | 4,916 (67.2)                              |         |
| Age at first birth?                   |                                        |                                           |         |
| <19                                  | 107 (46.9)                             | 2,997 (54.0)                              |         |
| 19–24                                | 100 (43.9)                             | 2,249 (40.6)                              | .001    |
| ≥25                                  | 21 (9.2)                               | 299 (5.4)                                 |         |

Abbreviations: DPO, Depo-Provera; IUCD, intrauterine contraceptive device.

physiological changes because of pregnancy and lactation, 12 (6.1%) had bacterial infection or breast abscess, and 49 (19.9%) had a palpable breast mass or nipple discharge, which met criteria for ultrasound-guided FNAC or cytologic examination. On final pathology review of those 49 cases, the most common diagnosis was benign breast disease (Fig. 2). Five patients (10.2%) were diagnosed with BC after clinical examination and FNAC.

### Clinical Presentation and Physical Examination of Women with Breast Abnormalities

We calculate the prevalence of BC to be 66 per 100,000 adult women (95% CI, 8–123 per 100,000). When including the two cases of already confirmed BC in our survey population, we calculated the prevalence of BC among rural women as 92 per 100,000 women (95% CI, 24–161 per 100,000). The mean age of women with BC was 58 ± 7.8 years. Of the women aged >49 years, nine presented with breast abnormalities, and four were diagnosed with breast cancer, whereas only 1 of 40 (81.6%) women aged <50 was diagnosed with BC. In contrast, the mean age of women with benign breast diseases was younger, 36 ± 1.5 years. We found that BC was associated with the age group ≥49 years (p < .002) and with age at first birth (p < .001). The mean duration of illness for women with BC was 6 ± 1.5 years, whereas the mean duration of illness was 2.7 ± 0.7 years for women with benign breast diseases (p = .001). The average size of the mass for patients with BC was 6 cm. The mean size of the benign breast masses was 2.2 cm.

Two women interviewed had been previously diagnosed with BC. The first patient, who was aged 56 years and had received surgery, was taking adjuvant tamoxifen with regular follow-up and surveillance. The second patient was aged 78 years and had been referred to the capital city of Addis Ababa for treatment. She declined to travel to Addis Ababa because she reported a negative perception of the outcome.

Five women who participated in the survey were ultimately diagnosed with BC. The first patient, aged 80 years, presented with a locally advanced ulcerated lesion >5 cm, was referred for care within the health system, was found to have metastatic disease, and then received tamoxifen. The second patient, aged 56 years, presented with an inoperable ulcerated breast lesion greater than 5 cm. She declined all forms of treatment because of negative perceptions about the outcome and ultimately died 9 months after her diagnosis at home. The third patient, aged 48 years, presented with an ulcerating inoperable tumor measuring 4 cm, was found to have metastatic disease, and received tamoxifen. The fourth patient, aged 35 years, presented with an ulcerating tumor measuring 3 cm (grade 1), received tamoxifen, and died 6 months after her diagnosis. The fifth patient, aged 70 years, presented with an ulcerating 3 cm breast mass and declined surgery and all forms of treatment, stating, “I do not want to lose my breast.”

### Future Burden of BC and Breast Abnormalities in Ethiopia

We projected our findings to the general population of Ethiopian women and also accounted for anticipated population growth over the next 10 years. We found that the number of self-reported breast abnormalities could increase from 1.0–1.1 million in 2018 to 1.3–1.5 million in 2028. We project 196,868 to 210,604 breast abnormalities could have met the criteria for ultrasound-guided FNAC in 2018 in the entire country. When projected to 2028, we calculate that 241,263 to
281,777 women would need diagnostic services around the country, an estimated 647 per 100,000 adult women. The projected BC numbers will increase from an estimated 27,967 (95% CI, 4,759–51,175) in 2018 to 39,552 (95% CI, 6,667–72,436) in 2028, with a prevalence rate of 92 per 100,000 adult women. The average percentage increase in absolute number of BC cases between 2018 and 2028 is 32.6%–33.8%. The annual average percentage increase is 3.3%–3.4% per year. We categorized the data in three age groups. The projected increase in BC cases among women aged 35 to 49 years will increase from 6,509 in 2018 to 9,616 in 2028, a 47.7% increase. We predict that the prevalence of BC in 2028 will be 90 per 100,000 adult women in this age bracket. For women aged ≥50 years, the number of BC cases will increase from 21,406 in 2018 to 30,112 in 2028, a 40.7% increase (Fig. 3). The prevalence for this age group will be 366 per 100,000 adult women.

**DISCUSSION**

This study is, to our knowledge, the first large population-based study to assess self-reported breast abnormalities among adult women in rural Ethiopia. We observed that self-breast awareness in 7,573 rural women was low. Importantly, 84.5% of women reported they never had examined their breasts, and 96.6% of women stated that they did not have a breast abnormality. This study enabled the unique opportunity to educate over 7,573 women about breast health.
awareness. We were able to further evaluate 246 women with self-reported abnormalities, confirmed 49 breast masses by physical examination that met criteria for FNAC, and found seven cases of BC in the region. Three women who otherwise would not have received any attention for their BCs were linked with oncologic care services within the region. We have projected the future needs for breast care in the Ethiopian health care system, focusing on the rural population.

The magnitude of future cases of breast abnormalities, demand for diagnostic services, and need for treatment of BC cases were projected for the next 10 years based on predictions for population growth and aging in the country. The proportion of women with self-reported breast abnormalities in our normal population was 3.4%, which was similar to studies from other African countries [22, 26]. These findings were lower than a study conducted in Malawi that reported a prevalence of 7% with regard to breast abnormalities [27]. This difference could be explained by the fact that the researchers in that study used trained breast health workers to examine breast abnormalities; therefore, this method may have had a higher probability of identifying abnormalities compared with the method of self-reporting abnormalities. The major limitation of our study is that it may underestimate the actual burden of disease. We predict, based on population changes alone, that the future demand for breast diagnosis in the next 10 years will be 1.5 million for women with self-reported breast abnormalities.

We project that 281,777 women with breast abnormalities may meet the criteria for FNAC, and we project that 40,254 BC cases could be identified. A limitation of this study is that we projected future disease burden by extrapolating our regional survey data to make predictions for the national burden, assuming a quickly growing and aging population. We believe that these data to a certain extent reflect the actual population because our sample survey of women in the rural region consisted of demographic characteristics, like age distribution and rural residence, that mirror the national composition of the population. We did not adjust our projections for rural/urban differences because few urban women were included in our sample. In an area without diagnostic service or breast cancer screening program, we were unable to assess the incidence of breast cancer.

We were able to survey behaviors of women when they self-detected an abnormality and found that few sought medical attention. This finding is consistent with another study that showed a high unmet need of addressing breast abnormalities in developing countries because of the low severity of symptoms, financial constraints within the health care system, low awareness about breast abnormalities among health care professionals and the public, and general lack of access to medical care [28].

We were able to provide further analysis of the underlying diagnosis in 3.4% of patients who self-detected their abnormalities, and we identified associated factors. A considerable number of young women in our study reported cyclical breast swelling, tenderness, and pain, which might be explained by hormonal changes related to lactation, pregnancy, and the menstrual cycle in a young age group.

In our study, a higher proportion of BC was diagnosed among women over the age of 49 years who complained of a breast abnormality. This finding concurred with findings from Rwanda that reported a higher proportion of BC cases among women aged ≥50 years with a palpable mass [29].

For those women with a confirmed palpable breast mass who underwent ultrasound-guided FNAC by a surgeon, the majority had benign breast disease. We found seven women with BC. These findings were lower than a study conducted in Kenya that reported 14 cases of BC among 1,094 adult women [30]. This difference could be explained by the fact that our study population was younger and BC was diagnosed only in women with self-reported breast abnormalities; we have not been able to detect BC among asymptomatic women. Those with confirmed cases of BC had late stage disease. In five cases, these women with BC were not aware of their disease. The low awareness about breast cancer and treatment may be due to a variety of reasons, including lack of health care seeking behavior, lack of access to BC diagnostic services, and lack of routine BC early detection programs in the country [10]. Had these women not participated in our survey, it is quite possible they could have remained untreated for their disease and ultimately died in their homes, without knowledge of the cause of death. As a result of participating in our survey, three women received tamoxifen treatment, and two declined any formal treatment.

This survey allowed us to interview seven rural women who we diagnosed with BC, discuss their perceptions of the disease, and follow their clinical course. Two women died 9 months after their diagnoses; they had declined oncologic care. The major reasons were related to their negative perception about outcome, fear of mastectomy, and no knowledge of any BC survivors. All seven women perceived being diagnosis with BC as a death sentence. We observed that the late presentation of BC with unfavorable outcome was contributing to the negative perception about BC. Raising awareness that the early detection of BC improves outcomes is needed.

The findings in our study underestimated the disease burden of breast abnormalities because clinical examination was performed only on symptomatic patients. Nevertheless, it provides a starting point to plan resource allocation in the health care system. In accordance with the National Cancer Control Plan, the Ethiopian health care system is improving access to adequate breast diagnostic and treatment facilities in rural part of the countries to respond to the unmet needs of breast abnormalities among women. The population is aging, and resource allocation for future cancer control initiatives needs to be planned. When the country increases breast awareness, it would be informative to survey this region again and find out if BCs are detected at earlier stages of disease.

As the country develops education initiatives to increase breast awareness among rural women, the findings from our survey of this area will be informative. We found the majority of women were married, Muslim, between the ages of 25 and 49 years, and perceived themselves as of “medium” economic status. The majority of women had children, and approximately 50% were using forms of...
contraception. Therefore, opportunities for increasing breast awareness could exist in the clinical setting where women receive gynecologic care. Barriers to seeking breast care may also involve the following: level of education and access to information, perceptions of the female body and breast examination, fears of the diagnostic and treatment interventions, and balancing other family needs, such as being mothers and caregivers [28, 31–35]. Such factors should be considered when developing educational materials with small focus groups to assess the effectiveness of messaging and content.

Evaluating palpable breast masses with ultrasound-guided FNAC offers a cost-effective approach for the early detection of BC in less developed countries that lack routine BC screening programs with mammography [36]. In a low-income country like Ethiopia, where more than three-fourths of the female population is aged <50 years, mammographic BC screening is not recommended [37].

CONCLUSION
A considerable prevalence of self-reported breast abnormalities of 3.4% among nearly 8,000 women and seven BC cases were found in rural Ethiopia. Only half of the women knew about and only one in eight had practiced breast self-examinations in the past. Only one-third of the women sought formal health care after being aware of abnormal breast changes. Breast awareness campaigns may inform the population. Of seven BC cases, only two had been diagnosed before. The other patients had clinically locally advanced disease, but even after a confirmed diagnosis, only three women opted for care within the health care system. This vicious cycle of late presentation, short survival, and fatalistic attitude in patients must be addressed.

The Ethiopian national cancer control initiatives must respond to the increasing burden of BC in rural and urban areas and address the need for breast examination, diagnostic services, and treatment. Ethiopia’s health care system should develop tailored interventions to track BC at an early stage. Initiatives could mobilize groups of BC survivors, who may play an important role to raise awareness, alter negative perceptions, and inform ways to improve care in a complex health care system.

ACKNOWLEDGMENTS
We acknowledge Martin Luther and Addis Ababa Universities, Butajira Health and Demographic Surveillance Site, health center and hospital management and staff for their cooperation. We also acknowledge Dr. Eyase Elias (surgeon), Dr. Shamsu Semen (surgeon), Dr. Shamsu Abraham (pathologist), and Maria Eckenweber, as well as all study participants, health extension workers, and data collectors. This study was supported by a grant from the Susan G. Komen Graduate Training in Disparities Research grant 16378013. Open Access funding enabled and organized by ProjekT DEAL.

AUTHOR CONTRIBUTIONS
Conception/design: Wondimu Ayele, Adamu Addissie, Andreas Wienke, Susanne Unverzagt, Ahmedin Jemal, Lesley Taylor, Eva J. Kantelhardt
 Provision of study material or patients: Wondimu Ayele
 Collection and/or assembly of data: Wondimu Ayele, Adamu Addissie
 Data analysis and interpretation: Wondimu Ayele, Adamu Addissie, Andreas Wienke, Susanne Unverzagt, Ahmedin Jemal, Lesley Taylor, Eva J. Kantelhardt
 Manuscript writing: Wondimu Ayele, Adamu Addissie, Andreas Wienke, Susanne Unverzagt, Ahmedin Jemal, Lesley Taylor, Eva J. Kantelhardt
 Final approval of manuscript: Wondimu Ayele, Adamu Addissie, Andreas Wienke, Susanne Unverzagt, Ahmedin Jemal, Lesley Taylor, Eva J. Kantelhardt

DISCLOSURES
The authors indicated no financial relationships.

REFERENCE
1. World Health Organization; International Agency for Research on Cancer. Cancer Today. Available at https://gco.iarc.fr/today-online-analysis [table, 2018]. Accessed August 2019.
2. Memirie ST, Habtemariam MK, Asefa M et al. Estimates of cancer incidence in Ethiopia in 2015 using population-based registry data. J Glob Oncol 2018;4:1–11.
3. Timoteowos G, Solomon A, Mathewos A et al. First data from a population-based cancer registry in Ethiopia. Cancer Epidemiol 2018;53:93–98.
4. Kantelhardt EJ, Zerche P, Mathewos A et al. Breast cancer survival in Ethiopia: A cohort study of 1,070 women. Int J Cancer 2014;135:702–709.
5. Deressa BT, Cihoric N, Badra EV et al. Breast cancer care in northern Ethiopia—cross-sectional analysis. BMC Cancer 2019;19:393.
6. Becker N, Junkermann H. Benefit and risk of mammography screening: Considerations from an epidemiological viewpoint [in German]. Dtsch Arztebl Int 2008;105:131–136.
7. Nelson HD, Tyne K, Naik A et al. Screening for breast cancer can update for the US Preventive Services Task Force. Ann Int Med 2009;151:727–742.
8. Gatzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane Database Syst Rev 2011;(1):CD001877.
9. Li J, Shao Z. Mammography screening in less developed countries. Springerplus 2015;4:615.
10. Pace LE, Keating NL. A systematic assessment of benefits and risks to guide breast cancer screening decisions. JAMA 2014;311:1327–1335.
11. Pace LE, Shulman LN. Breast cancer in sub-Saharan Africa: Challenges and opportunities to reduce mortality. The Oncologist 2016;21:739–744.
12. Agarwal G, Ramakant P. Breast cancer care in India: The current scenario and the challenges for the future. Breast Care (Basel) 2008;3:21–27.
13. Miller AB, Baines CJ. The role of clinical breast examination and breast self-examination. Prev Med 2011;53:118–120.
14. Pagani C, Coscia DR, Dellabianca C et al. Ultrasound guided fine-needle aspiration cytology of breast lesions. Ultrasound 2011;14:182–187.
15. Ly A, Ono JC, Hughes KS et al. Fine-needle aspiration biopsy of palpable breast masses: Patterns of clinical use and patient experience. J Natl Compr Canc Netw 2016;14:527–536.
16. Layfield LJ, Chrischilles EA, Cohen MB et al. The palpable breast nodule: A cost-effectiveness analysis of alternate diagnostic approaches. The role of the needle aspiration biopsy. Cancer 1993;72:1642–1651.
17. Anderson BO, Shyyan R, Eniu A et al. Breast cancer in limited-resource countries: An overview of the Breast Health Global Initiative 2005 guidelines. Breast J 2006;12(suppl 1):53–515.
18. National Comprehensive Cancer Network. NCCN Harmonized Guidelines for Sub-Saharan Africa: Breast Cancer. Version 2, 2017. Available at https://www.nccn.org/professionals/physician_gls/pdf/breast_harmonized-africa.pdf.
19. Abudris DO, Elsheikh A, Ali M et al. Breast cancer screening with trained volunteers in a rural area of Sudan: A pilot study. Lancet Oncol 2013;14:363–370.
20. Federal Ministry of Health Ethiopia: National Cancer Control Plan of Ethiopia 2016–2020. Available at https://www.iccp-portal.org/sites/default/files/plans/NCCP%20Ethiopia%20Final%2020261015.pdf. Accessed August 2019.

© 2021 The Authors. The Oncologist published by Wiley Periodicals LLC on behalf of AlphaMed Press.
21. INDEPTH Network. Butajira HDSS. Available at http://www.indepth-network.org/member-centres/butajira-hdss. Accessed August 2019.

22. Ntirenganya F, Petroze RT, Kamara, TB et al. Prevalence of breast morbidities and barriers to care: Results from a population-based survey in Rwanda and Sierra Leone. J Surg Oncol 2014; 110:903–906.

23. Ethiopia Central Statistical Agency. Statistical concepts and definitions. 2016. Available at https://international.ipums.org/international/resources/enum_materials_pdf/enum_instruct_et2007a.pdf. Accessed February 2021.

24. Ethiopia Central Statistical Agency. Population Projection 2007–2037, 2013. Available at https://www.statsethiopia.gov.et/wp-content/uploads/2019/05/ICPS-Population-Projection-2007-2037-produced-in-2012.pdf. Accessed February 2021.

25. United Nations, Department of Economic and Social Affairs, Population Division. World Population Prospects 2019.

26. Ströbele L, Kantelhardt EJ, Traoré Millogo TFD et al. Prevalence of breast-related symptoms, health care seeking behavior and diagnostic needs among women in Burkina Faso. BMC Public Health 2018;18:447.

27. Gutnik L, Lee C, Msosa V et al. Clinical breast examination screening by trained laywomen in Malawi integrated with other health services. J Surg Res 2016;204:61–67.

28. Shulman LN, Willett W, Sievers A et al. Breast cancer in developing countries: Opportunities for improved survival. J Oncol 2010;2010:595167.

29. Pace LE, Dusengimana JM, Hategekimana V et al. Benign and malignant breast disease at Rwanda’s first public cancer referral center. The Oncologist 2016;21:571–575.

30. Sayed S, Moloo Z, Ngugi A et al. Breast camps for awareness and early diagnosis of breast cancer in countries with limited resources: A multidisciplinary model from Kenya. The Oncologist 2016;21:1138–1148.

31. Akuoko CP, Armah E, Sarpong T et al. Barriers to early presentation and diagnosis of breast cancer among African women living in sub-Saharan Africa. PLoS One 2017;12:e0171024.

32. Heidari M, Ghodusi M. The relationship between body esteem and hope and mental health in breast cancer patients after mastectomy. Indian J Palliat Care 2015;21:198–202.

33. Gebremariam A, Dereje N, Addissie A et al. Factors associated with late-stage diagnosis of breast cancer among women in Addis Ababa, Ethiopia. Breast Cancer Res Treat 2021;185:117–124.

34. Getachew S, Tesfaw A, Kaba M et al. Perceived barriers to early diagnosis of breast cancer in south and southwestern Ethiopia: A qualitative study. BMC Womens Health 2020: 20:38.

35. Gebremariam A, Addissie A, Worku A et al. Time intervals experienced between first symptom recognition and pathologic diagnosis of breast cancer in Addis Ababa, Ethiopia: A cross-sectional study. BMJ Open 2019;9:e032228.

36. Yu Y, Wei W, Liu J. Diagnostic value of fine-needle aspiration biopsy for breast mass: A systematic review and meta-analysis. BMC Cancer 2012;12:41.

37. United Nations Development Programme (UNDP). Ethiopia: National Human Development Report 2018. Industrialization with a Human Face. UNDP Ethiopia, 2018. Available at http://hdr.undp.org/sites/default/files/ethiopia_national_human_development_report_2018.pdf.